Decompensated heart failure: a reconceptualization in the light of updated consensus statement of the European Society of Cardiology
V. N. Larina,
V. A. Kokorin,
V. G. Larin,
V. I. Lunev,
N. A. Suvorova,
I. K. Skiba,
E. S. Shcherbina https://doi.org/10.15829/1560-4071-2023-5581
EDN: EPVZVH
Abstract
The article presents a brief analytical review of the European Society of Cardiology consensus statement on the definition and clinical features of heart failure (HF) with a summary of the latest results on the treatment and prevention of exacerbation. The main viewpoints are compared with existing approaches in the Russian Federation. The definition and classification of worsening HF (WHF), as well as its main clinical manifestations, epidemiology, outcomes, pathophysiology, approaches to early detection, patterns of in- and outpatient treatment of WHF are discussed. Attention is paid to the terminology necessary to identify a cohort of patients with HF exacerbation with a previously established diagnosis of HF in order to unify approaches to diagnosis and treatment.
About the Authors
V. N. Larina
Pirogov Russian National Research Medical University
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
None
V. A. Kokorin
Pirogov Russian National Research Medical University
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
None
V. G. Larin
Pirogov Russian National Research Medical University
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
None
V. I. Lunev
Pirogov Russian National Research Medical University
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
None
N. A. Suvorova
Pirogov Russian National Research Medical University
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
None
I. K. Skiba
Pirogov Russian National Research Medical University
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
None
E. S. Shcherbina
Pirogov Russian National Research Medical University
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
None
References
1. Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272-87. doi:10.1093/cvr/cvac013.
2. Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14. (In Russ.) doi:10.18087/cardio.2021.4.n1628.
3. Bragazzi NL, Zhong W, Shu J, et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol. 2021;28(15):1682-90. doi:10.1093/eurjpc/zwaa147.
4. Metra M, Tomasoni D, Adamo M, et al. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2023;25(6):776-91. doi:10.1002/ejhf.2874.
5. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) doi:10.15829/1560-4071-2020-4083.
6. Zhirov IV, Nasonova SN, Tereshchenko SN. Acute decompensation of heart failure: state of the problem. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(9):1047-51. (In Russ.) doi:10.26442/00403660.2022.09.201839.
7. Boytsov SA, Tereshchenko SN, Villevalde SV, et al. Practical aspects of vericiguat therapy in patients with heart failure with reduced ejection fraction. Expert council resolution. Russian Journal of Cardiology. 2023;28(4):5423. (In Russ.) doi:10.15829/1560-4071-2023-5423
8. Abdullaev OA, Arutyunov AG, Vereshchak DP, et al. Combined diuretic therapy during decompensation of heart failure. 2023;1:40-4. (In Russ.) doi:10.24412/2071-5315-2023-12951.
9. Kristjánsdóttir I, Thorvaldsen T, Lund LH. Congestion and Diuretic Resistance in Acute or Worsening Heart Failure, Cardiac Failure Review. 2020;6:e25. doi:10.15420/cfr.2019.18
10. Greene SJ, Bauersachs J, Brugts JJ, et al. Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week. J Am Coll Cardiol. 2023;4(81):413-24. doi:10.1016/j.jacc.2022.11.023.
11. Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129-200. doi:10.1093/eurheartj/ehw128.
12. Koziolova NA, Veklich AS, Karavaev PG. Risk factors for acute decompensated heart failure in type 2 diabetes patients. Russian Journal of Cardiology. 2020;25(4):3717. (In Russ.) doi:10.15829/1560-4071-2020-4-3717
13. Teplov VM, Polushin YuS, Povzun AS, et al. In-patient emergency department and its role in the optimization of operation in intensive care departments of a multi-specialty hospital. Messenger of anesthesiology and resuscitation. 2017;3(14):5-9. (In Russ.) doi:10.21292/2078-5658-2017-14-3-5-9.
14. Fomin IV. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016;(8):7-13. (In Russ.) doi:10.15829/1560-4071-2016-8-7-13.
15. Vinogradova NG, Polyakov DS, Fomin IV. The risks of re-hospitalization of patients with heart failure with prolonged follow-up in a specialized center for the treatment of heart failure and in real clinical practice. Kardiologiia. 2020;60(3):59-69. (In Russ.) doi:10.18087/cardio.2020.3.n1002.
16. Greene SJ, Triana TS, Ionescu-Ittu R, et al. Patients hospitalized for de novo versus worsening chronic heart failure in the United States. J Am Coll Cardiol. 2021;77:1023-5. doi:10.1016/j.jacc.2020.12.026.
17. Kaplon-Cieslicka A, Benson L, Chioncel O, et al. Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction — insights from the ESC-HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2022;24:335-50. doi:10.1002/ejhf.2408.
18. Solovyeva AE, Kobalava ZD, Villevalde SV, et al. Prognostic value of liver stiffness in decompensated heart failure: results of prospective observational transient elastography-based study. Kardiologiia. 2018;58(10S):20-32. (In Russ.) doi:10.18087/cardio.2488.
19. Veklich AS, Koziolova NA. Features of acute decompensation of heart failure in patients with type 2 diabetes mellitus with anemia and latent iron deficiency. South Russian Journal of Therapeutic Practice. 2021;2(4):33-42. (In Russ.) doi:10.21886/2712-8156-2021-2-4-33-42.
20. Koziolova NA, Mironova SV, Ulybina EV. Acute decompensated heart failure in patients with prediabetes: relationship with risk factors and comorbidities. Russian Journal of Cardiology. 2023;28(3):5373. (In Russ.) doi:10.15829/1560-4071-2023-5373.
21. Rosano GMC, Moura B, Metra M, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021;23(6):872-81. doi:10.1002/ejhf.2206.
22. Butler J, Yang M, Manzi MA, et al. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019;73(8):935-44. doi:10.1016/j.jacc.2018.11.049.
23. Arutyunov AG, Rylova AK, Arutyunov GP. Register of hospitalized patients with circulatory decompensation (Pavlovsky register). Message 1. Modern clinical characteristics of a patient with circulatory decompensation. Clinical phenotypes of patients. Journal of Heart Failure. 2014;82(1):23-31. (In Russ.)
24. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75. doi:10.1056/NEJMoa010713.
25. Skali H, Dwyer EM, Goldstein R, et al. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. Eur J Heart Fail. 2014;16:560-5. doi:10.1002/ejhf.71.
26. Docherty KF, Jhund PS, Anand I, et al. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPAHF. Circulation. 2020;142:1623-32. doi:10.1161/CIRCULATIONAHA.120.047480.
27. Lam CSP, Giczewska A, Sliwa K, et al.; VICTORIA Study Group. Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA trial. JAMA Cardiol. 2021;6:706-12. doi:10.1001/jamacardio.2020.6455.
28. Polyakov DS, Fomin IV, Vaysberg AR. EPOCHA-D-CHF: gender differences in the prognosis of patients with CHF after acute decompensation (part 2). Kardiologiia. 2019;59(4S):33-43. (In Russ.) doi:10.18087/cardio.2654
29. Khan MS, Greene SJ, Hellkamp AS, et al. Diuretic changes, health care resource utilization, and clinical outcomes for heart failure with reduced ejection fraction: from the Change the Management of Patients with Heart Failure Registry. Circ Heart Fail. 2021;14:e008351. doi:10.1161/CIRCHEARTFAILURE.121.008351.
30. Ambrosy AP, Parikh RV, Sung SH, et al. Analysis of worsening heart failure events in an integrated health care system. J Am Coll Cardiol. 2022;80:111-22. doi:10.1016/j.jacc.2022.04.045.
31. Lediakhova MV, Zhirov IV, Nasonova SN, et al. Acute kidney injury in acute decompensated heart failure: possibility of early diagnosis. Emergency Cardiology. 2018;4:3-13. (In Russ.) doi:10.25679/EMERGCARDIOLOGY.2019.82.12.001.
32. Boorsma EM, Ter Maaten JM, Damman K, et al. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol. 2020;17:641-55. doi:10.1038/s41569-020-0379-7.
33. Okunev IM, Kochergina AM, Kashtalap VV. Chronic and acute decompensated heart failure: topical issues. Complex Issues of Cardiovascular Diseases. 2022;11(2):184-95. (In Russ.) doi:10.17802/2306-1278-2022-11-2-184-195.
34. Garganeeva AA, Kuzheleva EA, Mareev VYu. Euvolemia as a criterion of diuretic therapy efficacy in chronic heart failure: Literature review. The Siberian Journal of Clinical and Experimental Medicine. 2020;35(2):13-25. (In Russ.) doi:10.29001/2073-8552-2020-35-2-13-25
35. Larina VN, Golovko MG, Zakharova MI, et al. Clinical and prognostic significance of bendopnea in elderly outpatients. Cardiovascular Therapy and Prevention. 2019;18(6):45-50. (In Russ.) doi:10.15829/1728-8800-2019-6-45-50.
36. Kobalava ZD, Tolkacheva VV, Sarlykov BK, et al. Integral assessment of congestion in patients with acute decompensated heart failure. Russian Journal of Cardiology. 2022;27(2):4799. (In Russ.) doi:10.15829/1560-4071-2022-4799.
37. Gheorghiade M, Follath F, Ponikowski P, et al. European Society of Cardiology; European Society of Intensive Care Medicine. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail. 2010;12(5):423-33. doi:10.1093/eurjhf/hfq045.
38. Alvarez-Garcia J, Ferrero-Gregori A, Puig T, et al.; Investigators of the Spanish Heart Failure Network (REDINSCOR). A simple validated method for predicting the risk of hospitalization for worsening of heart failure in ambulatory patients: the Redin-SCOR E. Eur J Heart Fail. 2015;17:818-27. doi:10.1002/ejhf.287.
39. Sartipy U, Goda A, Yuzefpolskaya M, et al. Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for heart transplantation. Am Heart J. 2014;168:325-31. doi:10.1016/j.ahj.2014.03.025.
40. Codina P, Lupón J, Borrellas A, et al. Head-to-head comparison of contemporary heart failure risk scores. Eur J Heart Fail. 2021;23:2035-44. doi:10.1002/ejhf.2352.
41. Lee DS, Straus SE, Farkouh ME, et al.; COACH Trial Investigators. Trial of an intervention to improve acute heart failure outcomes. N Engl J Med. 2023;388:22-32. doi:10.1056/NEJMoa2211680.
42. Ter Maaten JM, Kremer D, Demissei BG, et al. Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. Eur J Heart Fail. 2019;21: 732-43. doi:10.1002/ejhf.1437.
43. Davison BA, Senger S, Sama IE, et al. Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF. Eur J Heart Fail. 2021;23:43-57. doi:10.1002/ejhf.2077.
44. Nunez J, Bayes-Genis A, Revuelta-Lopez E, et al. Clinical role of CA125 in worsening heart failure: a BIOSTAT-CHF study subanalysis. JACC Heart Fail. 2020;8:386-97. doi:10.1016/j.jchf.2019.12.005.
45. Chatur S, Vaduganathan M, Peikert A, et al. Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial. Eur J Heart Fail. 2022;24:1906-14. doi:10.1002/ejhf.2638.
46. Alekhin MN. Lung ultrasonography in the diagnosis of extravascular lung water. Creative Cardiology. 2015;1:27-37. (In Russ.) Алехин М.Н. Ультразвуковое исследование легких для диагностики внесосудистой жидкости. Креативная кардиология. 2015;1:27-37. doi:10.15275/kreatkard.2015.01.03.
47. Price S, Platz E, Cullen L, et al. Expert consensus document: Echocardiography and lung ultrasonography for the assessment and management of acute heart failure. Nature Reviews Cardiology. 2017;7(14):427-40. doi:10.1038/nrcardio.2017.56.
48. Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. 2021;398:991-1001. doi:10.1016/S0140-6736(21)01754-2.
49. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24:4-131. doi:10.1002/ejhf.2333.
50. Mullens W, Dauw J, Martens P, et al.; ADVOR Study Group. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387:1185-95. doi:10.1056/NEJMoa2203094
51. Mebazaa A, Solal AC, Colombo PC. Assessing and treating congestion in acute decompensated heart failure: are we seeing the light at the end of the tunnel? Eur Heart J. 2023;44:51-3. doi:10.1093/eurheartj/ehac680.
52. Fonarow GC, Abraham WT, Albert NM, et al. Influence of a Performance-Improvement Initiative on Quality of Care for Patients Hospitalized with Heart Failure: Results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Archives of Internal Medicine. 2007;167(14):1493-502. doi:10.1001/archinte.167.14.1493.
53. Fomin IV, Vinogradova NG, Polyakov DS, Pogrebetskaya VA. Experience of introducing a new form of organization of medical care for patients with heart failure in the Russian Federation. Kardiologiia. 2021;61(3):42-51. (In Russ.) doi:10.18087/cardio.2021.3.n1005.
54. Girerd N, Mewton N, Tartiere JM, et al. Practical outpatient management of worsening chronic heart failure. Eur J Heart Fail. 2022;24:750-61. doi:10.1002/ejhf.2503.
55. Gilotra NA, Princewill O, Marino B, et al. Efficacy of intravenous furosemide versus a novel, pH-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure. JACC Heart Fail. 2018;6:65-70. doi:10.1016/j.jchf.2017.10.001.
56. Mentz RJ, Ward JH, Hernandez AF, et al. Rationale, design and baseline characteristics of the PARAGLIDE-HF trial: sacubitril/valsartan vs valsartan in HFmrEF and HFpEF with a worsening heart failure event. J Card Fail. 2023;29(6):922-30. doi:10.1016/j.cardfail.2023.02.001.
57. Belenkov YuN, Arutyunov GP, Mareev VYu, et al. Prospects for use of Vericiguat in HFrEF: Implications of VICTORIA Trial Results. Advisory Board Summary. Kardiologiia. 2023;63(4):3-10. (In Russ.) doi:10.18087/cardio.2023.4.n2403.
Supplementary files
What is already known about the subject?
- Worsening of heart failure (HF) remains a serious problem due to limited opportunities for timely diagnosis and treatment, especially in the prehospital stage.
What might this study add?
- Exacerbation episodes are varied, and the risk of repeated HF deterioration is determined by residual congestion (clinical or subclinical).
- Due to the unfavorable prognosis, the phenotype of "hospitalized patients with decompensated HF" should be distinguished.
How might this impact on clinical practice?
- The introduction of a Russian- language analogue of the term "worsening HF" seems rational to identify a cohort of patients with HF exacerbation and an established diagnosis of HF in order to unify terminology and optimize management tactics.
Review
For citations:
Larina V.N., Kokorin V.A., Larin V.G., Lunev V.I., Suvorova N.A., Skiba I.K., Shcherbina E.S. Decompensated heart failure: a reconceptualization in the light of updated consensus statement of the European Society of Cardiology. Russian Journal of Cardiology. 2023;28(12):5581. (In Russ.) https://doi.org/10.15829/1560-4071-2023-5581. EDN: EPVZVH
Views:
8899
Email this article 